Fractional Erbium YAG Laser vs Intradermal and Systemic Tranexamic Acid
ConditionRefractory Melasma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorEgymedicalpedia
About this trial
Melasma is a common acquired disorder of hyperpigmentaion caused by increased melanin production by melanocytes.
Melasma is a name derived from the Greek word melas meaning black.It is characterized by the appearance of brownish or grayish symmetrical patches on sun-exposed skin, most commonly on the face. Compared to men, women are more likely to be affected.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Pregnancy
Lactation
Administration of oral contraceptive pills or any phototoxic drug within 1 month prior to study
Patients with a history of thrombosis, abnormal bleeding profile, known hypersensitivity to TA or HQ, and endocrinal disease.
Trial design
Design model
Crossover
Treatments tested in this trial
Tranexamic acid injection
Drugto evaluate and compare efficacy of: * Fractional Er: YAG laser combined with topical hydroquinone. * Intradermal injection of tranexamic acid combined with topical hydroquinone cream. * Oral administration of tranexamic acid combined with topical hydroquinone cream. In treating refractory melasma.
Treatment groups
45 Participants
are divided into 3 treatment groupsGroup A: Group AActive comparator 1 intervention
Group B: Group BActive comparator 1 intervention
Group C: Group CActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Refractory Melasma Treatment combination with topical hydroquinone
to detect the treatment response by YAG laser vs intradermal and systemic tranexamic acid by using The MASI index ( MASI is an index designed to quantify the severity of melasma during therapy).
Time frame
3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Egymedicalpedia
Lead sponsor
Aswan University
Collaborator
Source ClinicalTrials.gov